ESAB’s (NYSE:ESAB) Q2 CY2026 Sales Beat Estimates

ESAB (NYSE:ESAB) reported Q2 CY2026 revenue of $807.6 million, up 12.9% year over year, exceeding Wall Street estimates by 2.6%. Non-GAAP EPS was $1.33, down from $1.36 a year earlier and 3% below consensus. Operating margin fell to 9.7% from the prior year. Analysts expect full-year EPS to rise from $5.31 to $6.08.

Original reporting
Published Aug 6, 2026, 2:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 3:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ESAB’s (NYSE:ESAB) Q2 CY2026 Sales Beat Estimates — source image
Decision brief

The 30-second read

$ESABNeutralMed
01

Why it matters

Traders may reprice ESAB based on the combination of a revenue beat, an adjusted EPS miss, and a sharp year-over-year operating margin decline, while also weighing the forward EPS growth expectation.

02

Market read

This is a mixed earnings update: top-line outperformance versus profitability and EPS underperformance, with forward EPS growth cited as a potential offset.

03

What to watch

Organic revenue was flat over two years, implying the headline growth may be supported by acquisitions/FX rather than underlying demand strength.

Relevance 7/10Novelty 7/10Timing: post-Q2 release, same-day reaction described

Background

ESAB is a welding and cutting equipment manufacturer, and the article frames its Q2 CY2026 results versus revenue and EPS expectations.

Company-level read

Ticker impact

$ESABNeutralMedium confidence
Context

ESAB reported Q2 CY2026 revenue of $807.6M, up 12.9% YoY, beating Wall Street estimates by 2.6%.

Expected impact

Likely supports the stock on revenue momentum, but margin/EPS weakness may cap upside and keep traders focused on forward EPS growth.

Evidence & confidence

The article cites a revenue beat (+12.9% YoY, +2.6% vs estimates) alongside adjusted EPS of $1.33 missing consensus and operating margin falling to 9.7% from the prior year.

Market effects

Signals demand may be stabilizing enough for revenue growth, but profitability leverage is not yet improving for industrial welding/cutting equipment.

No explicit regional demand or FX/geography breakdown provided.

No explicit global macro or supply-chain shock details beyond organic revenue being flat.

Counterpoint

The revenue beat plus expected full-year EPS growth (+14.6%) could outweigh the margin drop if costs normalize in coming quarters.

Key entities

  • ESAB

    Reported Q2 CY2026 revenue beat, adjusted EPS miss, and operating margin decline; provided forward-looking EPS growth expectation.

Related articles

$ESABHigh

ESAB Corp (ESAB): Results of Operations and Financial Condition

ESAB Corp (ESAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningspressrelease.htm EX-99.1 Document ESAB Corporation Announces Second Quarter 2026 Results • Record total sales increased 12.9%, with core organic sales up 2.5% • Core organic growth in both segments • Closed Eddyfi ahead of schedule • Updating 2026 outlook

$ESABMed

Q4 Results 29th May Live: Asian Paints, IndiGo, NMDC, Glenmark Pharma, Ipca Lab, IREDA, Gujarat Gas, Natco Pharma, Inox Wind, Rubicon Research, BEML, NMDC Steel, JM Financial, Triveni Engg to announce

The article previews Q4 results from multiple Indian companies and highlights several earnings updates. Prime Focus reported standalone net profit of Rs 4.32 crore for March 2026 quarter vs Rs 16.11 crore loss a year earlier. Alkem Laboratories’ standalone net profit fell to Rs 217 crore from Rs 276.9 crore; it recommended a final dividend of Rs 10/share. It also cites Q4FY26 figures for ESAB India, Ecos Mobility, and Ivalue Infosolutions, plus early stock moves.

$JANMedAI 8/10

JAN Q2 Earnings Call Highlights

Janus Living (NYSE:JAN) reported sequential same-store NOI margin down 40 bps, citing seasonality. Occupancy rose for independent living but fell for skilled nursing. The company acquired two communities for $105M, sold one for $23M, and completed $1B more acquisitions post-quarter. It raised 2026 FFO guidance to $0.95-$0.98 and same-store adjusted NOI growth to 13%-17%.

$JOBYMedAI 8/10

Joby Aviation Q2 Earnings Call Highlights

Joby Aviation (NYSE:JOBY) raised full-year revenue guidance to $115 million to $125 million from $105 million to $115 million. Q2 cash use was about $202 million and GAAP net loss was $245 million, including a $108 million non-cash warrant and earn-out fair value change. For 2H 2026, it expects $385 million to $415 million cash use. The company said aircraft availability is a key constraint on Blade routes and outlined manufacturing, infrastructure, and JV plans with Toyota.

$JHXMedAI 8/10

James Hardie Industries Q1 Earnings Call Highlights

James Hardie (NYSE:JHX) said about one-third of fiber-cement growth came from strategic initiatives, one-third from prior-year destocking comparisons, and the rest from price and mix. June sell-through rose 19%. Deck, Rail & Accessories sales fell 5% to $305.1M with 27.1% Adjusted EBITDA margin. Q2 net sales forecast $1.485B-$1.575B and FY2027 outlook raised; FCF Q1 was $254M and it redeemed $400M notes.

$IXMed

Orix Corp Ads Q1 Earnings Call Highlights

ORIX (NYSE: IX) discussed Q1 results and outlook on an earnings call, including potential Q3 Kioxia sale and valuation losses tied to Kioxia’s end-September share price. ORIX shifted its dividend basis to adjusted profits, targeting an interim dividend of JPY 107.27 per share and full-year JPY 187.36. It reported JPY 115.7B capital gains and about JPY 300B capital-recycling inflows, and continued a JPY 250B buyback.